Skip to main content

Table 1 Baseline demographics of patients with idiopathic pulmonary fibrosis before and after propensity score matching – initial respiratory hospitalizations

From: Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications

  Before propensity score matching After propensity score matching
No Rx (N = 2511) Pirfenidone/Nintedanib (N = 402) Std. Diff No Rx (N = 402) Pirfenidone/Nintedanib (N = 402) Std. Diff
Age group
45–64 339 (13.5%) 53 (13.2%) − 0.009 55 (13.7%) 53 (13.2%) − 0.015
65–74 713 (28.4%) 163 (40.5%) 0.258 162 (40.3%) 163 (40.5%) 0.005
75 +  1459 (58.1%) 186 (46.3%) − 0.239 185 (46.0%) 186 (46.3%) 0.005
Gender
Female 1182 (47.1%) 125 (31.1%) − 0.332 132 (32.8%) 125 (31.1%) − 0.037
Male 1329 (52.9%) 277 (68.9%) 0.332 270 (67.2%) 277 (68.9%) 0.037
Race
White 1676 (66.7%) 293 (72.9%) 0.134 290 (72.1%) 293 (72.9%) 0.017
Black 365 (14.5%) 33 (8.2%) − 0.200 40 (10.0%) 33 (8.2%) − 0.061
Hispanic 311 (12.4%) 47 (11.7%) − 0.021 48 (11.9%) 47 (11.7%) − 0.008
Other 159 (6.3%) 29 (7.2%) 0.035 24 (6.0%) 29 (7.2%) 0.050
Census region
Midwest 704 (28.0%) 110 (27.4%) − 0.015 103 (26.5%) 110 (27.4%) 0.039
Northeast 399 (15.9%) 56 (13.9%) − 0.055 61 (15.2%) 56 (13.9%) − 0.035
South 1184 (47.2%) 201 (50.0%) 0.057 208 (51.7%) 201 (50.0%) − 0.035
West 224 (8.9%) 35 (8.7%) − 0.008 30 (7.5%) 35 (8.7%) 0.046
Baseline comorbidities
Cardiac Arrhythmia 1037 (41.3%) 129 (32.1%) − 0.192 113 (28.1%) 129 (32.1%) 0.087
Congestive Heart Failure 976 (38.9%) 108 (26.9%) − 0.257 97 (24.1%) 108 (26.9%) 0.063
Other Chronic Pulmonary Conditions 1833 (73.0%) 260 (64.7%) − 0.180 261 (65.0%) 260 (64.7%) − 0.005
Depression 501 (20.0%) 72 (17.9%) − 0.052 68 (16.9%) 72 (17.9%) 0.026
Diabetes 973 (38.7%) 146 (36.3%) − 0.050 136 (33.8%) 146 (36.3%) 0.052
Hypertension 1934 (77.0%) 279 (69.4%) − 0.173 275 (68.4%) 279 (69.4%) 0.021
Pulmonary Circulation Disorder 644 (25.6%) 112 (27.9%) 0.050 112 (27.9%) 112 (27.9%) 0.000
Renal Failure 603 (24.0%) 72 (17.9%) − 0.150 70 (17.4%) 72 (17.9%) 0.013
Solid Tumor without Metastasis 347 (13.8%) 59 (14.7%) 0.025 65 (16.2%) 59 (14.7%) − 0.041
Valvular Disease 642 (25.6%) 70 (17.4%) − 0.199 74 (18.4%) 70 (17.4%) − 0.026
Elixhauser comorbidity index
Mean (SD) 5.7 (3.4) 4.7 (2.8) − 0.344 4.5 (2.9) 4.7 (2.8) 0.062
Median 5.0 4.0 −  4.0 4.0
Q1, Q3 3.0, 8.0 3.0, 6.0 −  2.0, 6.0 3.0, 6.0
N hospitalizations in baseline
0 1452 (57.8%) 315 (78.4%) 0.452 316 (78.6%) 315 (78.4%) − 0.006
1 662 (26.4%) 70 (17.4%) − 0.218 73 (18.2%) 70 (17.4%) − 0.020
2 +  397 (15.8%) 17 (4.2%) − 0.393 13 (3.2%) 17 (4.2%) 0.053
Year of hospitalization
2015 561 (22.3%) 36 (9.0%) − 0.375 37 (9.2%) 36 (9.0%) − 0.009
2016 604 (24.1%) 115 (28.6%) 0.104 127 (31.6%) 115 (28.6%) − 0.065
2017 661 (26.3%) 131 (32.6%) 0.138 118 (29.4%) 131 (32.6%) 0.070
2018 685 (27.3%) 120 (29.9%) 0.057 120 (29.9%) 120 (29.9%) 0.000
Reason for admission
Diseases of respiratory system 1393 (55.5%) 158 (39.3%) − 0.328 155 (38.6%) 158 (39.3%) 0.015
Diseases affecting the interstitium 928 (37.0%) 239 (59.5%) 0.462 243 (60.4%) 239 (59.5%) − 0.020
All other reasons 190 (7.6%) 5 (1.2%) − 0.312 4 (1.0%) 5 (1.2%) 0.024
Pulmonologist visit 1323 (52.7%) 323 (80.3%) 0.613 322 (80.1%) 323 (80.3%) − 0.006
Smoker 1274 (50.7%) 198 (49.3%) − 0.030 205 (51.1%) 198 (49.3%) − 0.035
Steroid use 1351 (53.8%) 229 (57.0%) 0.064 227 (56.5%) 229 (57.0%) 0.010
Oxygen use 1482 (59.0%) 320 (79.6%) 0.424 310 (77.1%) 320 (79.6%) 0.006